Borderline pulmonary pressures in scleroderma - a 'pre-pulmonary arterial hypertension' condition?

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Kovacs, Gabor ^a,b   Olschewski, Horst ^a,b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARDIOLIPIN ANTIBODY; ANTIHYPERTENSIVE AGENT;

ALGORITHM; CLINICAL FEATURE; COMORBIDITY; DISEASE ASSOCIATION; EDITORIAL; EVIDENCE BASED MEDICINE; FORCED VITAL CAPACITY; HUMAN; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; PERIPHERAL EDEMA; PROGNOSIS; PULMONARY HYPERTENSION; SCLERODERMA; SYSTEMIC SCLEROSIS; TELANGIECTASIA; COHORT ANALYSIS; DISEASE COURSE; FEMALE; HYPERTENSION, PULMONARY; INCIDENCE; LUNG WEDGE PRESSURE; MALE; PHYSIOLOGY; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; MALE; PROGNOSIS; PULMONARY WEDGE PRESSURE; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 85019225811     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0649-7     Document Type: Editorial

References (9)

1. Visovatti SH, Distler O, Coghlan J, Denton CP, Grunig E, Bonderman D, et al. Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Res Ther. 2014;16:493.
2. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179:151-7.
3. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809-15.
4. Valerio CJ, Schreiber BE, Handler CE, Denton CP, Coghlan JG. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum. 2013;65:1074-84.
5. Kovacs G, Avian A, Tscherner M, Foris V, Bachmaier G, Olschewski A, et al. Characterization of patients with borderline pulmonary arterial pressure. Chest. 2014;146:1486-93.
6. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981;36:752-8.
7. Coghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73:1340-9.
8. Saggar R, Khanna D, Shapiro S, Furst DE, Maranian P, Clements P, et al. Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study. Arthritis Rheum. 2012;64:4072-7.
9. Kovacs G, Maier R, Aberer E, Brodmann M, Graninger W, Kqiku X, et al. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum. 2012;64:1257-62.